Emerging Strategies in Stimuli-Responsive Nanocarriers as the Drug Delivery System for Enhanced Cancer Therapy.

Emerging Strategies in Stimuli-Responsive Nanocarriers as the Drug Delivery System for Enhanced Cancer Therapy. Curr Pharm Des. 2019;25(24):2609-2625 Authors: Saravanakumar K, Hu X, Ali DM, Wang MH Abstract The conventional Drug Delivery System (DDS) has limitations such as leakage of the drug, toxicity to normal cells and loss of drug efficiency, while the stimuli-responsive DDS is non-toxic to cells, avoiding the leakage and degradation of the drug because of its targeted drug delivery to the pathological site. Thus nanomaterial chemistry enables - the development of smart stimuli-responsive DDS over the conventional DDS. Stimuliresponsive DDS ensures spatial or temporal, on-demand drug delivery to the targeted cancer cells. The DDS is engineered by using the organic (synthetic polymers, liposomes, peptides, aptamer, micelles, dendrimers) and inorganic (zinc oxide, gold, magnetic, quantum dots, metal oxides) materials. Principally, these nanocarriers release the drug at the targeted cells in response to external and internal stimuli such as temperature, light, ultrasound and magnetic field, pH value, redox potential (glutathione), and enzyme. The multi-stimuli responsive DDS is more promising than the single stimuli-responsive DDS in cancer therapy, and it extensively increases drug release and accumulation in the targeted cancer cells, resulting in better tumor cell ablation. In this regard, a handful of multi-stimuli responsive DDS is in clinical tri...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research

Related Links:

This study sought to evaluate the prevalence of menopausal symptoms in a population of reproductive-aged women remote from cancer therapy compared with a group of healthy similar-aged controls and with a cohort of late reproductive-aged (LR) controls.MethodsParticipants were assessed for symptoms of menopause, early follicular phase hormones, and ultrasound examinations. Menopausal symptoms were analyzed in exposed participants and controls usingχ2 analyses, Wilcoxon-Mann Whitney tests, and multivariable logistic regression models.ResultsOne hundred seventy cancer survivors, 135 similar-aged controls, and 71 LR control...
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
Lantheus Medical Imaging parent Lantheus Holdings has announced the ongoing...Read more on AuntMinnie.comRelated Reading: Lantheus reports revenue increases for Q4, 2019 Lantheus touts new study on contrast echocardiography Lantheus appoints new CCO Lantheus hires former Bayer director as new CMO Lantheus, CarThera partner on ultrasound cancer therapy
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
In this study, we first found that Low-intensity ultrasound (LIUS) was capable of reducing the CSC populations in the xenograft model with ovarian cancer, with blocking survival, anti-apoptosis, self-renewal, and downregulating the cancer stemness genes in ovarian CSCs. Moreover, LIUS ameliorated IL-6/STAT3 inflammatory pathway via inhibiting IL-6-induced STAT3 phosphorylation, DNA binding activity and, the expressions of its downstream effectors in ovarian CSCs while no explicit effect was found in the corresponding bulk cancer cells. Additional approaches in molecular studies showed that LIUS disrupts CSC features via in...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Lantheus Medical Imaging parent Lantheus Holdings has reported growth in 2019...Read more on AuntMinnie.comRelated Reading: Lantheus touts new study on contrast echocardiography Lantheus appoints new CCO Lantheus hires former Bayer director as new CMO Lantheus, CarThera partner on ultrasound cancer therapy Lantheus posts lower Q3 results
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Lantheus Medical Imaging parent Lantheus Holdings has reported growth in 2019...Read more on AuntMinnie.comRelated Reading: Lantheus touts new study on contrast echocardiography Lantheus appoints new CCO Lantheus hires former Bayer director as new CMO Lantheus, CarThera partner on ultrasound cancer therapy Lantheus posts lower Q3 results
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Abstract Pharmacotherapy and imaging are two critical facets of cancer therapy. Carbon nanotubes and their modified species such as magnetic or gold nanoparticle conjugated ones they have been introduced as good candidates for both purposes. Gold nanoparticles enhance effects of X-rays during radiotherapy. Nanomaterial-mediated radiofrequency (RF) hyperthermia refers to using RF to heat tumors treated with nanomaterials for cancer therapy. The combination of hyperthermia and radiotherapy, synergistically, causes a significant reduction in X-ray doses. The present study was conducted to investigate the ability and ...
Source: Applied Biochemistry and Biotechnology - Category: Biochemistry Authors: Tags: Appl Biochem Biotechnol Source Type: research
Both photodynamic therapy (PDT) and sonodynamic therapy (SDT) are fast growing activated therapies by using light or ultrasound to initiate catalytic reaction of sensitizing agents, showing great potentials in clinics because of high safety and noninvasiveness. Sensitizers are critical components in PDT and SDT. Sinoporphyrin sodium (DVDMS) is an effective constituent derived from Photofrin that has been approved by FDA. This review is based on previous articles that explore the applications of DVDMS mediated photodynamic/sonodynamic cancer therapy and antimicrobial chemotherapy. Researchers utilize different cell lines, d...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Lantheus Medical Imaging parent company Lantheus Holdings announced the results...Read more on AuntMinnie.comRelated Reading: Lantheus appoints new CCO Lantheus hires former Bayer director as new CMO Lantheus, CarThera partner on ultrasound cancer therapy Lantheus posts lower Q3 results Lantheus to acquire Progenics
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
A new form of low-intensity pulsed ultrasound therapy shows promise for destroying...Read more on AuntMinnie.comRelated Reading: Lantheus, CarThera partner on ultrasound cancer therapy Postsurgery ultrasound doesn't help fractured tibias Bioventus launches ultrasound system in Saudi Arabia Ultrasound may treat epileptic seizures
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Clinical Trials | Drugs & Pharmacology | Nanotechnology | Organic | Toxicology | Ultrasound | Zinc